Blog

Mediktor closes a funding round of 3 million euros with the aim of entering the US market

Ronda-MediktorFrom left to right: Cristian Pascual, CEO and co-founder of Mediktor; Oscar García-Esquirol, CMO and co-founder of Mediktor; Peter Vanhecke, Partner and co-founder of Castel Capital; Josep Carbó, director Global Business Development and partner of Mediktor; Miguel Valls, General Partner of Alta Life Sciences; Jéromine Kalfon, Project Manager and Business Development & Open Innovation of Naos; Jean-Yves Desmottes, Vice President of Operations of Naos. 

 

The round led by Alta Life Sciences, will reinforce the most advanced and accurate symptom checker, the only clinically validated in the world.

Start-up investors such as European-focused Castel Capital, French-based Naos, as well as other “business angels”, have also joined the round.

 

Mediktor announces the closure of a Series A funding round for an amount of 3 million euros. Alta Life Sciences Spain I FCR (“ALSS I FCR”) as leading investor in Mediktor, advised by Alta Life Sciences, leads the round that has been closed today and which includes Castel Capital, a European-focused venture capital investor; also French-based Naos, international reference in the field of skin care (Bioderma Laboratories); as well as other minority partners, many of whom were already “business angels” of the company.

The round provides the necessary impetus to support the commercialization of the Artificial Intelligence application in the North American market, to reinforce and improve the tool both technically and scientifically to continue with the company’s goal, which is to provide the tool with greater clinical validation. To this end, Mediktor is already collaborating in an alliance with Hospital Clínic in Barcelona, making the platform the only clinically validated in the world with a success rate of 91.3% proven in clinical trials.

Miguel Valls, partner of Alta Life Sciences, commented: “Mediktor technology reduces barriers to health care. Patients are empowered to be able to make better decisions from the first symptoms and the health system may be able to organize their demand and optimize resources to offer better medical coverage”.

“We are very pleased to count on the force and solidity of this great team. Alta Life Sciences from Silicon Valley and Barcelona, Castel Capital from the Netherlands and Naos with its international experience will help us to break into the US market strongly” remarked Cristian Pascual, CEO and co-founder of Mediktor.

       


           

About Mediktor

Mediktor is the most advanced and accurate symptom checker for pre-diagnosis, triage and decision-making support. The technology combines artificial intelligence, natural language recognition and patient data to detect symptoms and offer a listing of possible conditions, recommendations and even connecting with medical professionals within a health insurance network.

The platform learns from every interaction, developing an advanced intuition. Mediktor has already performed 2 million symptom evaluations in more than 200 countries globally developing an intuition comparable to a full life experience of 10 physicians. The platform has undergone a clinical study with 1,015 patients achieving a success rate of 91.3% accuracy.

Founded in 2011 by Oscar García-Esquirol, doctor specialist in intensive care medicine and Cristian Pascual, industrial engineer & MBA, based in Barcelona with an office in New York. Mediktor has a multidisciplinary team of health professionals, computer scientists, experts in business development and external advisors. The company is partnering with major insurance companies and main referral hospitals across the world, including Münich RE Group, an international reinsurance company, represented in over 30 countries and concentrated on Europe and Asia.

www.mediktor.com 

info@mediktor.com 

@Mediktor

About Alta Life Sciences

Alta Life Sciences with origins in Silicon Valley and specialized in companies in the life sciences sector in Spain and abroad is a leading multistage venture capital investment advisory firm. Alta Life Sciences targets companies at all stages of development: from seed financing through commercial growth in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

Alta Life Sciences Spain I FCR (“ALSS I FCR”) is a bridge fund, focused in the Spanish life sciences ecosystem and connecting both sides of the Atlantic, joining the Spanish life sciences ecosystem with the Venture Capital expertise of Silicon Valley. Alta Life Sciences is the exclusive advisor to ALS Spain I FCR. Altamar Private Equity SGIIC, a leading independent firm in the management of international Private Equity and other alternative assets, is ALSS I FCR’s management company.

Alta Life Sciences management team, led by Guy Nohra, is headquartered in Barcelona. The remainder of the team is formed by experienced life science professionals from the US and Spain.

About Castel Capital

Castel Capital (www.castelcapital.com) is a venture capital and private equity platform, focused on European opportunities. It is privately held and has a unique approach to working with co-investors as well as to sourcing deals. Castel Capital proactively works with all our portfolio companies and assist them with their growth path and value creation.

About Naos

NAOS is a purpose-driven company with a mission, inspired by a claimed humanist utopia. A way of looking at the world, the constant desire to question and challenge the status quo in order to build a future that will never forget its ultimate aim: humankind.

Thus, 40 years ago, Jean-Noël Thorel, a pharmacist-biologist, overthrew the established understanding of the beauty industry by giving birth to a disruptive but respectful approach: ecobiology, or the art of preserving the skin ecosystem by reinforcing its natural mechanisms. Rather than over-treating the skin, it must learn how to function properly.

From this idea the brands Bioderma, Institut Esthederm and Etat Pur were born, making NAOS a major international figure in Skincare.

Today, operating in 100 countries and still as fiercely independent as ever, NAOS has the ambition to become globally known for the universal value and the originality of its approach. To achieve this goal, NAOS will be extending its scope from Skincare to Human Care (Health, Beauty, Well-being).

 

2 October 2018

Share: